Please login to the form below

Gene editing

This page shows the latest Gene editing news and features for those working in and with pharma, biotech and healthcare.

Moderna and Life Edit partner to accelerate gene editing therapies

Moderna and Life Edit Therapeutics, an ElevateBio company, have entered into a strategic collaboration aimed at discovering and developing in vivo mRNA gene editing therapies for hard-to-treat diseases. ... The partnership will combine Life Edit's suite

Latest news

New T-cell study demonstrates ‘powerful’ potential for tailored cancer medicine

The results were published in a peer-reviewed paper in Nature. Patients diagnosed with untreatable cancers have been involved in a new experimental study exploring the potential of gene editing technology ... short palindromic repeats (CRISPR) technology,
ICR study raises possibility of predicting drug resistance in advance

The study, published in the journal Cancer Research, involved the use of the gene editing technology CRISPR to break or switch off each of 25, 000 genes in cancer cells treated ... and also led to increased activity of another gene called SMG1, which
Genentech and ArsenalBio join to identify successful T-cell oncology therapies

ArsenalBio’s engineering platform spans a range of cutting-edge technology, including high-throughput CRISPR-based gene editing, synthetic biology and computational biology, to create new synthetic biological programmes aimed at
Novartis and Precision BioSciences announce in vivo gene editing collaboration

Novartis and Precision BioSciences (Precision) have announced an in vivo gene editing research and development collaboration to develop potentially curative treatments for disorders including sickle cell disease (SCD) and beta thalassaemia.
AstraZeneca officially opens new R&D facility in UK

said. The Discovery Centre will support AstraZeneca’s focus on specialised and precision medicines and foster the discovery and development of next-generation therapeutics, including nucleotide-based, gene-editing and cell

More from news
Approximately 10 fully matching, plus 59 partially matching documents found.

Latest Intelligence

Gene therapy, gene editing and perspectives on future use in Parkinson’s disease

Gene editing describes the modification of a patient’s genome to treat a disease, using engineered or bacterial nucleases. ... Gene editing is a concept that has elicited discomfort and opposition from many who believe the potential for its misuse is
How early-stage clinical research is facilitating the new wave of personalised medicines

Lastly, gene editing is a hugely promising area for new drug development in which DNA is inserted, deleted, modified or replaced in a genome. ... One of these adaptations relates to patient enrolment. Whereas previously CROs were able to draw on a
Alzheimer’s: the search for a cure

gene-editing specialist Sangamo for rights to tau-targeting drug ST-501 as part of a broader R&D alliance. ... Such a shift has recently happened in the gene therapy space, which was a backwater pursued largely by biotech until the progress of companies
Novo Nordisk awakens its ‘Sleeping Beauty’

The next phases were to enrich the pipeline with acquisitions and partnerships, including a headline deal with blue-bird bio for next generation gene editing that could lead to a potential ... We also have a stem cell platform, gene editing, an exquisite
It started with a miss

There are huge implications for communications. Take gene editing, for example. ... We’re going to get to the point where treatments like gene therapies will be ubiquitous – so we need to set ourselves up for them now and embrace the ethical debate

More from intelligence
Approximately 2 fully matching, plus 16 partially matching documents found.

Latest appointments

Eric Rhodes becomes CEO of ERS Genomics

In these roles, Rhodes was responsible for commercialising the company's genome editing technologies as well as driving its research and development. ... Biosciences. Foy said: “With his deep understanding of the gene-editing landscape and extensive
Marc Becker joins CRISPR Therapeutics

He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia

Several manufacturers are developing novel treatments for the disease, including Vertex, which has partnered with CRISPR Therapeutics to develop a gene-editing treatment for beta-thalassemia and sickle cell. ... The move marks a continuation in its
Rare Disease Day – looking to the future with hope

In addition to pharmaceutical company involvement, several advocacy groups are also driving clinical research and the development of technologies such as gene therapy, gene editing and antisense oligonucleotides. ... 2021), examined the diagnostic
Disrupting Cell Engineering with Non-Viral Modalities

Jessica Schwaber, Scientific Director, Cell &Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell &gene therapy commercial needs, current barriers to realizing the full ... potential of cell &gene
Gene Editing and Precision Medicine: The Future of Healthcare?

Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine.
Spotlight interview: 15 minutes on medical and scientific writing

A number of current therapeutic approaches – such as gene editing, gene therapy, and stem-cell therapy – were not in existence when many healthcare professionals (HCPs) underwent their training, so there is